Consequences of thrombosis, whether in the arterial or in the venous system, or in the left atrium in patients with atrial fibrillation, are the most common causes of death. Therefore, great attention is given to the prevention and treatment of thrombosis in the present. The aim of this review article is to summarize the current knowledge on the laboratory and clinical monitoring of the antithrombotic treatment.
- Keywords
- antikoagulační léčba, protidestičková léčba,
- MeSH
- Anticoagulants administration & dosage adverse effects therapeutic use MeSH
- Aspirin administration & dosage adverse effects therapeutic use MeSH
- Fibrinolytic Agents administration & dosage adverse effects therapeutic use MeSH
- Financing, Organized MeSH
- Heparin, Low-Molecular-Weight administration & dosage adverse effects therapeutic use MeSH
- Heparin administration & dosage adverse effects therapeutic use MeSH
- Platelet Aggregation Inhibitors administration & dosage adverse effects therapeutic use MeSH
- Clinical Laboratory Techniques methods utilization MeSH
- Humans MeSH
- Meta-Analysis as Topic MeSH
- Drug Monitoring methods trends utilization MeSH
- Prothrombin Time utilization MeSH
- Statistics as Topic MeSH
- Ticlopidine analogs & derivatives administration & dosage therapeutic use MeSH
- Warfarin administration & dosage adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Review MeSH
- MeSH
- Erythrocytes physiology MeSH
- Blood Preservation methods trends utilization MeSH
- Blood Banking MeSH
- Blood Banks history trends MeSH
- Plasma physiology MeSH
- Blood Transfusion methods trends utilization MeSH
- Hemorrhage blood prevention & control MeSH
- Humans MeSH
- Prothrombin Time methods utilization MeSH
- Blood Component Removal methods trends utilization MeSH
- Platelet Transfusion methods utilization MeSH
- Check Tag
- Humans MeSH
- MeSH
- Patient Compliance MeSH
- Monitoring, Ambulatory methods utilization MeSH
- Anticoagulants administration & dosage adverse effects therapeutic use MeSH
- Clinical Laboratory Techniques instrumentation trends utilization MeSH
- Humans MeSH
- Drug Monitoring methods trends utilization MeSH
- Self Care methods trends utilization MeSH
- Prothrombin Time methods instrumentation utilization MeSH
- Quality Control MeSH
- Warfarin administration & dosage adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
- MeSH
- Factor IX antagonists & inhibitors pharmacology isolation & purification MeSH
- Factor VIII antagonists & inhibitors pharmacology isolation & purification MeSH
- Hemorrhagic Disorders diagnosis etiology MeSH
- Immunoglobulins pharmacology physiology MeSH
- Blood Coagulation Factor Inhibitors pharmacology isolation & purification MeSH
- Clinical Laboratory Techniques instrumentation trends utilization MeSH
- Humans MeSH
- Partial Thromboplastin Time methods instrumentation utilization MeSH
- Prothrombin Time methods instrumentation utilization MeSH
- Check Tag
- Humans MeSH
- MeSH
- Pharmacogenetics trends MeSH
- Genetic Association Studies MeSH
- Genetic Techniques utilization MeSH
- Humans MeSH
- Mixed Function Oxygenases * isolation & purification MeSH
- Polymorphism, Genetic MeSH
- Prothrombin Time utilization MeSH
- Statistics as Topic MeSH
- Cytochrome P-450 Enzyme System * metabolism MeSH
- Vitamin K isolation & purification metabolism MeSH
- Warfarin * pharmacokinetics metabolism MeSH
- Check Tag
- Humans MeSH
- MeSH
- Patient Compliance MeSH
- Diet Therapy MeSH
- Atrial Fibrillation drug therapy MeSH
- Drug Interactions MeSH
- Humans MeSH
- Drug Monitoring methods MeSH
- Prothrombin Time utilization MeSH
- Heart Valve Prosthesis MeSH
- Thromboembolism drug therapy prevention & control MeSH
- Vitamin K adverse effects MeSH
- Warfarin pharmacology adverse effects therapeutic use MeSH
- Check Tag
- Humans MeSH
Předpokládá se, že lupus antikoagulans (LA) může interferovat nejen s klinickým průběhem antikoagulační léčby, ale také se stanovením protrombinového času. Tak u nemocných s antifosfolipidovým syndromem vzniká otázka validity monitorování léčby warfarinem s použitím INR. K objasnění tohoto problému jsme srovnali hodnoty INR získané od dvou skupin nemocných na antikoagulační léčbě; jedna s přítomností LA a druhá bez tohoto nálezu, a to v průběhu jednoho roku. Neprokázali jsme žádné rozdíly při srovnání obou skupin nemocných co do klinického průběhu, relativního počtu hodnot INR pod či nad cílový terapeutický interval a počtu dní v cílovém terapeutickém rozmezí.
It has been suggested that lupus anticoagulants (LA) could interfere not only with clinical course of the oral anticoagulant treatment but also with determination of prothrombin time. Thus question of the validity of monitoring warfarin treatment using INR arises in patients with antiphospholipid syndrome. To clarify this point, we compared the values of INR obtained in the plasmas of two groups of patients on oral anticoagulant treatment; one with LA and the other one without LA, during one year period. We could not prove any differences comparing clinical course, relative number of INR values under or over target therapeutic interval and number of the days in the target therapeutic range between these two groups of the patients.
- MeSH
- Antiphospholipid Syndrome diagnosis complications therapy MeSH
- Anticoagulants administration & dosage therapeutic use MeSH
- International Normalized Ratio methods utilization MeSH
- Humans MeSH
- Lupus Vulgaris diagnosis complications therapy MeSH
- Prothrombin Time utilization MeSH
- Warfarin therapeutic use MeSH
- Check Tag
- Humans MeSH
